GlassScriptPhysician profile
Christine E Franden
NPI 1669459160
$4,479.64
in general payments reported to CMS, 2019-2025
35 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $435 · 2021: $1,110 · 2022: $526 · 2023: $466 · 2024: $937 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,021.05 | 2019-2025 | Krystexxa, Prolia, Evenity |
| Abbvie INC. | $391.88 | 2019-2025 | |
| Currax Pharmaceuticals LLC | $263.67 | 2021-2024 | Contrave, Onzetra Xsail, Nexlizet |
| Lilly USA, LLC | $255.75 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $213.24 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $187.89 | 2020-2024 | Airsupra |
| Azurity Pharmaceuticals, INC. | $166.66 | 2023-2024 | Edarbi, Horizant, Edarbi |
| Pfizer INC. | $163.87 | 2020-2025 | |
| Eisai INC. | $148.05 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $145.77 | 2020-2023 | Livalo, Seglentis |
| Boston Scientific Corporation | $130.19 | 2019-2020 | |
| Novo Nordisk INC | $125.70 | 2020-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $124.35 | 2019 | |
| Amneal Pharmaceuticals LLC | $124.14 | 2024-2025 | Unithroid |
| Allergan, INC. | $122.54 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $111.36 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lundbeck LLC | $109.32 | 2022 | |
| Glaxosmithkline, LLC. | $104.57 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Arbor Pharmaceuticals, INC. | $77.86 | 2020-2022 | |
| Astellas Pharma US INC | $66.35 | 2023 | Veozah |
| Axsome Therapeutics, INC. | $59.36 | 2024-2025 | Auvelity, Symbravo |
| Radius Health, INC. | $51.24 | 2019 | |
| Ibsa Pharma INC. | $44.37 | 2019-2020 | |
| Edwards Lifesciences Corporation | $38.53 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.25 | 2023-2024 | Trintellix |
| Therapeuticsmd, INC. | $30.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $24.26 | 2019 | |
| Sanofi Pasteur INC. | $22.03 | 2021 | |
| Mylan Specialty L.P. | $21.96 | 2021 | |
| Sumitomo Pharma America, INC. | $21.59 | 2025 | Gemtesa |
| Exact Sciences Corporation | $20.66 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $18.13 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $14.64 | 2020 | |
| Millicent US INC | $14.27 | 2021 | |
| Zyla Life Sciences, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Franden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.